Helmholtz Gemeinschaft


Targeting tachykinin receptors in neuroblastoma.

PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader

Item Type:Article
Title:Targeting tachykinin receptors in neuroblastoma.
Creators Name:Henssen, A.G. and Odersky, A. and Szymansky, A. and Seiler, M. and Althoff, K. and Beckers, A. and Speleman, F. and Schäfers, S. and De Preter, K. and Astrahanseff, K. and Struck, J. and Schramm, A. and Eggert, A. and Bergmann, A. and Schulte, J.H.
Abstract:Neuroblastoma is the most common extracranial tumor in children. Despite aggressive multimodal treatment, high-risk neuroblastoma remains a clinical challenge with survival rates below 50%. Adding targeted drugs to first-line therapy regimens is a promising approach to improve survival in these patients. TACR1 activation by substance P has been reported to be mitogenic in cancer cell lines. Tachykinin receptor (TACR1) antagonists are approved for clinical use as an antiemetic remedy since 2003. Tachykinin receptor inhibition has recently been shown to effectively reduce growth of several tumor types. Here, we report that neuroblastoma cell lines express TACR1, and that targeting TACR1 activity significantly reduced cell viability and induced apoptosis in neuroblastoma cell lines. Gene expression profiling revealed that TACR1 inhibition repressed E2F2 and induced TP53 signaling. Treating mice harboring established neuroblastoma xenograft tumors with Aprepitant also significantly reduced tumor burden. Thus, we provide evidence that the targeted inhibition of tachykinin receptor signaling shows therapeutic efficacy in preclinical models for high-risk neuroblastoma.
Keywords:Fosaprepitant, Aprepitant, Neuroblastoma, NK1R, Targeted Therapy, Animals, Mice
Publisher:Impact Journals
Page Range:430-443
Date:3 January 2017
Official Publication:https://doi.org/10.18632/oncotarget.13440
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library